Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.95 |
| ▸ | NPC1 | O15118 | 9/20 | 0.95 |
| ▸ | RAB9A | P51151 | 9/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.95 |
| ▸ | HTT | P42858 | 5/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | TP53 | P04637 | 4/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.95 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.95 |
| ▸ | PKM | P14618 | 1/20 | 0.95 |
| ▸ | HPGD | P15428 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | CCR1 | P32246 | 3/20 | 0.74 |
| ▸ | CCR5 | P51681 | 3/20 | 0.74 |
| ▸ | CCR8 | P51685 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | METAP1 | P53582 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456985 | 0.97 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL30211369 | 0.97 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL1456153 | 0.97 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4174742 | 0.95 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4189211 | 0.95 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4181725 | 0.90 | KDM4E (0.86) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| Dipyridyl SCHEMBL287597 | 0.89 | KDM4E (0.93) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| Dipyridyl SCHEMBL7900008 | 0.89 | KDM4E (0.93) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| Dipyridyl SCHEMBL1535115 | 0.89 | KDM4E (0.93) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL3753259 | 0.88 | KDM4E (0.82) | KDM4ENPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036418-A1 | Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient | INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY, THE (KR) | 2009-02-05 | — | — | US | claimed |
| US-20090036418-A1 | Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient | INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY, THE (KR) | 2009-02-05 | — | — | US | disclosed |
| WO-2007007943-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OF CANCER COMPRISING PYRIDYLPYRIDAZINE COMPOUNDS OR THEIR TRANSITION METAL COMPLEXES | THE INDUSTRY AND ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) (KR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036418-A1 | Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient | CA5A, PDCD11, PDCD1 | KDM4E 1038/4885NPC1 4803/4885RAB9A 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.